세계의 비경구 항생제 시장 : 시장 규모, 점유율, 성장 및 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of parenteral antibiotics Market

The global parenteral antibiotics market continues to expand as hospitals and critical care centers increasingly rely on intravenous (IV) and intramuscular (IM) antibiotic formulations to manage severe infections. According to the latest assessment, the market was valued at USD 24.22 billion in 2024, driven by rising hospital admissions, increasing prevalence of multidrug-resistant infections, and the widespread use of injectable antibiotics in emergency care. In 2025, the market is projected to grow to USD 25.09 billion, while long-term forecasts indicate a rise to USD 33.66 billion by 2032, reflecting a CAGR of 4.3% during the forecast period.

North America held the dominant market position in 2024, accounting for 45.5% of global revenue, equivalent to USD 11.02 billion. The region's strong clinical infrastructure, high diagnostic capabilities, and frequent use of parenteral therapies in intensive care settings continue to fuel demand. Major global companies-including Pfizer Inc., GSK plc, AbbVie Inc., Merck & Co., Inc., Bayer AG, and Bristol-Myers Squibb Company-play a significant role in shaping market performance through product launches, generic expansion, and antimicrobial innovation.

Market Dynamics

Market Drivers

A key driver of market growth is the increasing rate of hospitalizations due to severe infections, including pneumonia, septicemia, meningitis, urinary tract infections, and surgical site infections. Hospital-acquired infections (HAIs) significantly contribute to the need for parenteral therapy, especially in critical care units. According to WHO, 1 in 10 hospitalized patients worldwide is affected by HAIs, underscoring the growing reliance on injectable antibiotics.

Another strong driver is the rising population of immunocompromised patients, including cancer patients, transplant recipients, and individuals with HIV/AIDS-groups that often require rapid, high-potency antibiotic intervention. The emergence of Outpatient Parenteral Antibiotic Therapy (OPAT) also contributes to market expansion, enabling patients to receive intravenous antibiotics outside traditional hospital settings.

Market Restraints

Growth is hampered by barriers to antibiotic access in emerging markets. Weak healthcare infrastructure, limited cold-chain facilities, and high out-of-pocket expenses reduce the availability of quality parenteral medications. Dependence on select countries for active pharmaceutical ingredients (APIs) makes global supply chains vulnerable to disruptions and price fluctuations.

Additionally, the low profitability of antibiotic research and development remains a challenge. Short treatment durations, stewardship-driven restrictions, and rigorous regulatory pathways limit returns on investment, discouraging pharmaceutical innovation.

Market Opportunities

The rapid expansion of OPAT programs presents major opportunities for cost-effective parenteral antibiotic delivery. Studies have shown that OPAT can reduce treatment costs by 22%-42% compared to inpatient care, while improving patient comfort and freeing hospital resources. Growing payer support for OPAT and the rise of home-based healthcare models will create new revenue openings for manufacturers.

Market Challenges

Regulatory hurdles and complex approval requirements for injectable antibiotics prolong development timelines and increase production costs. Additionally, global efforts to reduce unnecessary antibiotic use may limit volume growth in certain regions.

Segmentation Highlights

By Drug Class

Penicillin led the market in 2024, supported by its broad availability, clinical effectiveness, and growing generic penetration. Cephalosporins also maintained a significant share due to their wide clinical application across multiple infection types. Macrolides, fluoroquinolones, and aminoglycosides are expected to record steady growth through 2032.

By Application

The respiratory infections segment held the largest share in 2024, driven by rising cases of pneumonia, tuberculosis, and sinusitis. The urinary tract infections (UTI) segment follows, supported by product introductions targeting complicated UTIs and hospital-acquired pathogens.

By Distribution Channel

Hospital pharmacies dominated the market in 2024 due to their central role in administering IV antibiotics. The online pharmacy segment is projected to grow fastest as digital adoption increases and home-based care expands.

Regional Insights

North America

Valued at USD 11.02 billion in 2024, North America will maintain leadership with strong antimicrobial stewardship programs, advanced diagnostics, and rapid adoption of innovative injectables.

Europe

Europe ranked second, supported by high antibiotic usage rates and strong regulatory oversight. Collaborative partnerships among manufacturers continue to strengthen the market landscape.

Asia Pacific

Asia Pacific is expected to grow at the fastest rate. Increasing approvals for injectable antibiotics, high infection burdens, and large populations accelerate regional demand.

Latin America & Middle East-Africa

These regions are poised for moderate growth as awareness programs expand and governments strengthen antimicrobial guidelines.

Conclusion

Growing from USD 24.22 billion in 2024 to USD 33.66 billion by 2032, the parenteral antibiotics market remains essential for managing severe infections worldwide. Rising HAIs, the adoption of OPAT, and expanding generic manufacturing will continue to shape market evolution over the next decade.

If you want, I can also prepare an SEO-optimized HTML version, regional deep-dive, or drug-class comparative analysis.

Segmentation By Drug Class

• Penicillin
• Cephalosporin
• Aminoglycosides
• Tetracycline
• Macrolides
• Fluoroquinolones
• Sulfonamides
• Others

By Application

• Skin Infections
• Respiratory Infections
• Urinary Tract Infections
• Septicemia
• Gastrointestinal Infections
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • U.S.
  • Canada
• Europe (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2024
• 4.2. Reimbursement Scenario, By Key Countries/Regions
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Overview: Technological Advancements in Parenteral Antibiotics Delivery
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Penicillin
  • 5.1.2. Cephalosporin
  • 5.1.3. Aminoglycosides
  • 5.1.4. Tetracycline
  • 5.1.5. Macrolides
  • 5.1.6. Fluoroquinolones
  • 5.1.7. Sulfonamides
  • 5.1.8. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Skin Infections
  • 5.2.2. Respiratory Infections
  • 5.2.3. Urinary Tract Infections
  • 5.2.4. Septicemia
  • 5.2.5. Gastrointestinal Infections
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacy
  • 5.3.2. Retail Pharmacy
  • 5.3.3. Online Pharmacy
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Penicillin
  • 6.1.2. Cephalosporin
  • 6.1.3. Aminoglycosides
  • 6.1.4. Tetracycline
  • 6.1.5. Macrolides
  • 6.1.6. Fluoroquinolones
  • 6.1.7. Sulfonamides
  • 6.1.8. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Skin Infections
  • 6.2.2. Respiratory Infections
  • 6.2.3. Urinary Tract Infections
  • 6.2.4. Septicemia
  • 6.2.5. Gastrointestinal Infections
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacy
  • 6.3.2. Retail Pharmacy
  • 6.3.3. Online Pharmacy
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Penicillin
  • 7.1.2. Cephalosporin
  • 7.1.3. Aminoglycosides
  • 7.1.4. Tetracycline
  • 7.1.5. Macrolides
  • 7.1.6. Fluoroquinolones
  • 7.1.7. Sulfonamides
  • 7.1.8. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Skin Infections
  • 7.2.2. Respiratory Infections
  • 7.2.3. Urinary Tract Infections
  • 7.2.4. Septicemia
  • 7.2.5. Gastrointestinal Infections
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Penicillin
  • 8.1.2. Cephalosporin
  • 8.1.3. Aminoglycosides
  • 8.1.4. Tetracycline
  • 8.1.5. Macrolides
  • 8.1.6. Fluoroquinolones
  • 8.1.7. Sulfonamides
  • 8.1.8. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Skin Infections
  • 8.2.2. Respiratory Infections
  • 8.2.3. Urinary Tract Infections
  • 8.2.4. Septicemia
  • 8.2.5. Gastrointestinal Infections
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Penicillin
  • 9.1.2. Cephalosporin
  • 9.1.3. Aminoglycosides
  • 9.1.4. Tetracycline
  • 9.1.5. Macrolides
  • 9.1.6. Fluoroquinolones
  • 9.1.7. Sulfonamides
  • 9.1.8. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Skin Infections
  • 9.2.2. Respiratory Infections
  • 9.2.3. Urinary Tract Infections
  • 9.2.4. Septicemia
  • 9.2.5. Gastrointestinal Infections
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacy
  • 9.3.2. Retail Pharmacy
  • 9.3.3. Online Pharmacy
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Parenteral Antibiotics Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Penicillin
  • 10.1.2. Cephalosporin
  • 10.1.3. Aminoglycosides
  • 10.1.4. Tetracycline
  • 10.1.5. Macrolides
  • 10.1.6. Fluoroquinolones
  • 10.1.7. Sulfonamides
  • 10.1.8. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Skin Infections
  • 10.2.2. Respiratory Infections
  • 10.2.3. Urinary Tract Infections
  • 10.2.4. Septicemia
  • 10.2.5. Gastrointestinal Infections
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacy
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Bristol-Myers Squibb Company
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Sandoz Group AG
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. GSK plc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bayer AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Merck & Co., Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Cipla
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. AbbVie Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. AdvaCare Pharma
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)